Frequently Asked Questions
The global biologics for systemic lupus erythematosus market was valued at USD 0.58 Billion in 2022.
The biologics for systemic lupus erythematosus market is expected to grow at a CAGR of 8.50% between 2023 and 2030, reaching USD 1.03 Billion in 2030.
Oral is the leading segment by route of administration outlook, holding over 35% share in terms of value in 2022.
The subcutaneous segment is expected to post the highest CAGR during the forecast period.
North America is fueling the growth of the biologics for systemic lupus erythematosus industry, with over one-third share in 2022.
The top players include Pfizer, Roche, GlaxoSmithKline, Sanofi, AbbVie, Novartis, Merck & Co., Bristol-Myers Squibb, Celgene, Janssen Global Services, LLC, Eli Lilly and Company, UCB, AstraZeneca, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Astellas Pharma, Inc., Biotest AG, and Coherus BioSciences.
SLE is becoming more common, especially among women of childbearing age, and affects millions of individuals globally are the major market drivers.
The major market restraints are insufficient access to care and knowledge about SLE, especially among healthcare professionals, which could lead to a false positive and delayed treatment.
Increasing R&D investment, The creation of novel SLE treatments is receiving significant funding from businesses and academic organizations, which are the major opportunities in the biologics for systemic lupus erythematosus industry.